October 12, 2023 11:23 AM EDT

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit

Amber Tong

Kyle LaHucik

Senior Reporter

Plus, Scholar Rock’s entry into the weight loss space, new funding for Synerkine Pharma and its lead pain program, BioLineRx’s Asia deal, Hansa Biopharma’s Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit

Amber Tong

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

CMS explains what went into its first round of drug price negotiations

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

FDA lifts hold on Pep­Gen's my­oton­ic dy­s­tro­phy drug; Take­da teams with can­cer non­prof­it

Senior Reporter

Sign up to read this article for free.

more like this

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit